Atlas Trials

Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

Clinical trial NCT07410559 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07410559
Sponsor
Fudan University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2026-07-01
Primary completion
2029-04-01
Enrollment
189

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.